...
首页> 外文期刊>Urology >Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms.
【24h】

Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms.

机译:前列腺特异性膜抗原在肾肿瘤的肿瘤相关新脉管系统中的表达。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVES: Prostate-specific membrane antigen (PSMA) is highly expressed in prostate cancer cells. Recently, PSMA has been found in the neovasculature in association with other solid malignant tumors, including clear cell renal carcinoma (RCC). We studied the expression of PSMA in different primary renal tumors. METHODS: A tissue microarray was constructed from 60 normal kidney, 21 clear cell RCC (CCRCC), 20 papillary RCC (PRCC), 16 chromophobe RCC, 19 oncocytoma, 14 transitional cell carcinoma, and 19 angiomyolipoma (AML) specimens. This tissue microarray was then immunostained for a vascular endothelial marker CD34 and PSMA. PSMA expression in CD34-positive tumor-associated neovasculature was scored according to the staining intensity and the percentage of vessels. Only diffuse strong or weak, or focal strong PSMA staining was graded as positive. RESULTS: PSMA was expressed in the proximal tubules of the normal kidney and in the tumor-associated vasculature in the renal tumors. Positive PSMA staining was detected in 76.2% of CCRCC, 31.2% of chromophobe RCC, 52.6% of oncocytoma, 21.4% of transitional cell carcinoma, and 0% of PRCC and AML specimens. Its expression was greater in CCRCC than PRCC, chromophobe RCC, transitional cell carcinoma, and AML (P <0.001), but was not significantly different from the expression in oncocytoma (P = 0.79). PSMA expression did not correlate with the pathologic stage in CCRCC. CONCLUSIONS: PSMA is differentially expressed in the tumor-associated neovasculature in different renal tumors. It is most commonly detected in CCRCC and rarely detectable in PRCC and AML. This finding suggests that antibodies against PSMA may potentially be used as a diagnostic marker and therapeutic target for renal neoplasms.
机译:目的:前列腺特异性膜抗原(PSMA)在前列腺癌细胞中高表达。最近,在新脉管系统中发现了PSMA与其他实体恶性肿瘤相关,包括透明细胞肾癌(RCC)。我们研究了PSMA在不同原发性肾肿瘤中的表达。方法:从60例正常肾脏,21例透明细胞RCC(CCRCC),20例乳头状RCC(PRCC),16例发色细胞RCC,19癌细胞瘤,14例移行细胞癌和19例血管平滑肌脂肪瘤(AML)标本中构建组织芯片。然后对该组织微阵列进行免疫染色以检测血管内皮标记物CD34和PSMA。根据染色强度和血管百分比对CD34阳性肿瘤相关新脉管系统中的PSMA表达进行评分。仅弥散性强或弱或局灶性强PSMA染色被定为阳性。结果:PSMA在正常肾脏的近端小管和肾肿瘤的与肿瘤相关的脉管系统中表达。在76.2%的CCRCC,31.2%的发色性RCC,52.6%的肿瘤细胞瘤,21.4%的移行细胞癌以及0%的PRCC和AML标本中检测到PSMA阳性。其在CCRCC中的表达高于PRCC,发色RCC,移行细胞癌和AML(P <0.001),但与在肿瘤细胞瘤中的表达无显着差异(P = 0.79)。 PSMA表达与CCRCC的病理分期无关。结论:PSMA在不同肾肿瘤的肿瘤相关新脉管系统中差异表达。它在CCRCC中最常检测到,而在PRCC和AML中则很少检测到。这一发现表明,针对PSMA的抗体可能被用作肾肿瘤的诊断标志物和治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号